Furthermore, in the Glycemic Effects in Diabetes Mellitus (GEMINI) trial comparing carvedilol and metoprolol on glycemic control in 1235 participants with hypertension and type 2 DM (HbA1c: 6.5–8.5%) on top of renin angiotensin RAS blockers, 40% fewer patients progressed to microalbuminuria in the carvedilol arm than in the metoprolol arm in hypertensive patients [46]. This evidence concerns the gene REN and diabetes mellitus.